Also, intranasal delivery generally produces fewer systemic side effects due to reduced peripheral exposure
Donanemab, another controversial drug which costs about 60-80,000 per year, shows a 0.7 point difference at 76 weeks, which is roughly 33% slower than placebo
Regulatory T cells (Tregs) are a CD4 + T and CD25 + subset of T lymphocytes with anti-inflammatory properties (119)
8 Reasons for less weight loss with GLP1 RAs for T2D could include use of insulin or other obesity-promoting medications, concerns over hypoglycemia, decreased glycosuria, microbiome variation, genetic predisposition towards weight gain, and differences in endogenous GLP-1 pathways in the brain and other tissues
This approach aims to increase the effectiveness of the therapy and support sustainable weight loss